Pegylated granulocyte colony-stimulating factor (G-CSF) has recently been introduced as a new compound for mobilization of CD34 + hematopoietic stem and progenitor cells. In this study, we compared the molecular and functional characteristics of CD34 + cells mobilized by pegylated G-CSF with those mobilized by unconjugated G-CSF.
Introduction
Peripheral blood stem and progenitor cells are widely utilized for autologous and allogeneic grafts as they provide rapid and sustained hematologic reconstitution following high dose chemotherapy. In order to obtain a sufficient harvest, stem cells can be mobilized into the peripheral blood using cytokines, cytotoxic chemotherapy or a combination of both.
1 Currently, granulocyte colonystimulating factor (G-CSF) is the most favored cytokine administered for peripheral blood stem cell mobilization because of its great efficacy and lack of serious toxicity. Recently, a modified form of recombinant human G-CSF has been introduced. This new compound is pegylated filgrastim (Peg-G-CSF) which has a 12-fold longer serum half-life than the unconjugated drug. Attachment of a polyethylene (glycol) moiety to recombinant human G-CSF reduces renal excretion and masks proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a single injection.
2-4
Following conventional cytotoxic chemotherapy, it has been observed that leukocyte recovery is more rapid and the occurrence of CD34 + cells in the peripheral blood earlier after administration of Peg-G-CSF in comparison to unconjugated G-CSF. 5, 6 The molecular causes underlying these different mobilization kinetics are unclear and the molecular characteristics and composition of Peg-G-CSFmobilized stem and progenitor cells has not been studied so far. However, it has been previously demonstrated that Peg-G-CSF-mobilized CD34 + cells and G-CSF-mobilized ones have different functional properties. Peg-G-CSF mobilization of CD34 + cells resulted in enhanced expansion of tolerogenic antigen-presenting cells and augmentation of regulatory T-cell activity following transplantation and thus promoted tolerance. 7, 8 In this study, we investigated the impact of Peg-G-CSF and unconjugated G-CSF at normalized cumulative doses on transcriptomal phenotype, subset composition and functional properties of CD34 + cells and Lin -, CD34 + , CD38 -hematopoietic stem cells.
Design and Methods

Patients and cells
After informed consent, peripheral blood mononuclear cells were obtained by density centrifugation from 16 patients with multiple myeloma. There were no statistically significant differences with regard to age, gender, body weight, stage and subtype of disease, previous therapy or disease status between the two groups subsequently given Peg-G-CSF or G-CSF. The patients' characteristics are given in more detail in Table 1 . Following induction therapy with a median of three (range, 2-6) cycles of 4ϫ10 mg/m 2 idarubicin p.o. and 4ϫ20 mg/m 2 dexamethasone p.o., all patients received a total dose of 4 g/m 2 cyclophosphamide administered on two consecutive days. Seven patients received a single dose of 6 mg Peg-G-CSF (median; range, 6-12 mg) 5 days (median; range, 4-6 days) after the end of chemotherapy. In the nine patients receiving unconjugated G-CSF a single subcutaneous injection was given once every day beginning 5 days (median; range, 4-8 days) after cytotoxic chemotherapy. The cumulative G-CSF dose administered was 6.2 mg (median; range, 4.3-15.4 mg). On a per kilogram basis the relative G-CSF dose was 109 µg (median; range, 76-197) in the Peg-G-CSF group and 111 µg (median; range, 54-256) in the G-CSF group. The dose on a per kilogram per day basis was 12 µg (median; range, 6-23) and 10 µg (median; range, 4-15) for the Peg-G-CSF group and G-CSF group, respectively. The collection of peripheral blood stem cells by apheresis was started in both groups of patients when a threshold concentration of 10 CD34 + cells/µL was reached in the peripheral blood. CD34 + cells were positively selected from apheresis products using the midiMACS immunomagnetic separation system (Miltenyi Biotec, Bergisch Gladbach, Germany) as described elsewhere. 9 Purities of CD34 + cell preparations varied between 97.9% and 99.8%.
RNA isolation, cRNA labeling and hybridization to microarrays
Total RNA (median: 6.0 µg; range, 1.5-35.5 µg) from isolated CD34 + cells was used to generate biotin-labeled cRNA (median: 27.2 µg; range, 4.8-105.3 µg) by means of the Enzo BioArray HighYield RNA Transcript Labeling Kit (Affymetrix Ltd, UK). Quality control of RNA and cRNA was performed using a bioanalyzer (Agilent 2001 Biosizing, Agilent Technologies). Following fragmentation, labeled cRNA from samples of each individual patient was hybridized to Affymetrix HG-Focus GeneChips (one array per patient's sample) covering 8793 genes and stained according to the manufacturer's instructions.
Quantification, normalization, and statistical analysis
Details on quality control, normalization and data analysis, are given in the Online Supplementary Data.
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-subsets, total RNA was isolated using the RNeasy micro kit (Qiagen, Hilden, Germany) adding 20 ng of bacterial rRNA as a carrier according to the manufacturer's instructions.
Cell cycle assays
Cell cycle analysis using BrdU and 7-amino-actinomycin D (7-AAD) staining was performed as described previously. 12 Student's t-test was used to assess statistically significant differences regarding cell cycle phases between the two groups given Peg-G-CSF or G-CSF (p<0.05). -hematopoietic stem cells was performed as described previously. 13 Cells were sorted and analyzed using a double laser (488 nm/350 nm Enterprise II +647 Spectrum) high-speed cell sorter (MoFlo MLS, Cytomation).
Immunofluorescence-based cell sorting
Semisolid clonogenic assays
Mononuclear cells and purified CD34 + cells were seeded in semisolid ready-to-use methylcellulose growth medium (MethoCult H4436, StemCell Technology, Vancouver, Canada) at concentrations ranging between 2ϫ10 4 and 5ϫ10 4 MNC/mL and 5ϫ10 2 and 1ϫ10 3 CD34 + cells/mL as described.
14 Colony numbers (CFU-GM, BFU-E) were counted after 2 weeks. Each experiment was performed in duplicate. The Student's t-test was used to detect statistically significant differences (p<0.05).
Results
In this study, we compared gene expression patterns, subset composition and functional properties of peripheral blood-derived CD34 + cells and highly purified hematopoietic stem cells obtained from patients with multiple myeloma following mobilization with cyclophosphamide and stimulation with either Peg-G-CSF or G-CSF. Approaching the period of leukopenia following a median time of 5 days after the end of chemotherapy, seven patients were given a single injection of Peg-G-CSF while nine patients received G-CSF on a daily basis resulting in an equal cumulative dose. Looking at a total of 8793 genes contained within the array we found that 339 genes were differentially expressed with a q-value below 5% and a fold change of at least 1.2. Comparing the two groups of patients, 222 genes had a higher expression level within the Peg-G-CSF-mobilized CD34 + cells and 117 genes had a lower one in comparison to the G-CSFmobilized CD34 + cells. Hierarchical cluster analysis on the basis of the differentially expressed genes reflected the distinct expression pattern of G-CSF and Peg-G-CSFmobilized cells and demonstrated the homogeneity of the cell samples of each group (Online Supplementary Figure 1) . Microarray gene expression analysis was performed in conformity with the latest consensus guidelines. 
Peg-G-CSF-mobilized peripheral blood stem cells show a gene expression pattern characteristic of immature progenitors
In Peg-G-CSF-mobilized CD34 + cells, we found a gene expression pattern reflecting a developmentally earlier progenitor cell type. Accordingly, in Peg-G-CSF-mobilized CD34 + cells significantly greater levels of the HOX family of homeobox genes such as HOXA9, HOXA10 and their positive regulator MLL as well as co-factor myeloid ecotropic viral integration site 1 homolog (MEIS1) were observed. On the other hand, genes associated with erythroid differentiation and late stages of myeloid matura- 
tion along the granulocytic lineage were expressed at 2-to 16-fold lower levels in Peg-G-CSF-mobilized CD34
+ cells compared to G-CSF-mobilized ones. These genes included β-globin and the global erythroid regulator and transcription factor Kruppel-like factor 1 (KLF1), 16 defensins α 1,3 and 4 and C/EBP β and δ as well as matrix metalloproteinases 8 and 9. In turn, PAWR (Par-4 receptor), a regulator of Wilm's tumor gene 1 (WT1) 17 and HOXA5 18 both of which are inhibitors of erythroid differentiation, showed a significantly higher expression level in Peg-G-CSF-mobilized cells.
Compared to G-CSF stimulation, Peg-G-CSF mobilizes a greater proportion of hematopoietic stem cells and common myeloid progenitors but fewer megakaryocyteerythrocyte progenitors
To address the question of whether the distinct expression patterns could result from a different progenitor subset composition (hematopoietic stem cells, common myeloid progenitors, granulocyte monocyte progenitors, megakaryocyte erythrocyte progenitors) in the peripheral blood after stimulation by either G-CSF or Peg-G-CSF, we examined five G-CSF-mobilized and five Peg-G-CSFmobilized CD34 + cell samples with regard to their subset composition. Peg-G-CSF-mobilized samples contained a greater proportion of hematopoietic stem cells (17.8%; SD: 2.1% vs. 14.1%; SD: 1.8%; p=0.038) and a higher fraction of common myeloid progenitors (40.9%; SD: 1.1% vs. 28.7%; SD: 4.4%; p=0.008) compared with G-CSFmobilized samples (Figure 2 ). In contrast, we found a significantly lower prportion of megakaryocyte erythrocyte progenitors (12.9%; SD:3.0% vs. 21.8%; SD:1.4%; p=0.005) in Peg-G-CSF-mobilized cells. These data demonstrate that the subset composition of Peg-G-CSFmobilized cells is different from that of G-CSF-mobilized cells and partially explains the more immature transcriptional profile with less proneness to erythroid differentiation.
Peg-G-CSF-mobilized PBSC favor granulocytic over erythroid colony formation
We hypothesized that the observed higher expression levels of genes important for early myeloid progenitors and, correspondingly, the greater proportion of common myeloid progenitors, combined with lower expression of erythropoiesis-related genes and the smaller proportion of megakaryocyte erythrocyte progenitors in Peg-G-CSFmobilized CD34 + cells are relevant for the colony-forming potential of these cells. To address this question, we utilized semisolid methylcellulose assays to determine clonogenic growth. Mononuclear cells as well as purified CD34 + cells obtained from patients who had received Peg-G-CSF were associated with significantly lower mean BFU-E/CFU-GM ratios than CD34 + cells from patients given G-CSF (p=0.038 and p=0.016, respectively) ( Figure 3A and B) .
Peg-G-CSF-mobilized peripheral blood stem cells express higher levels of proliferation-associated genes
We found seven differentially expressed genes involved in cell cycle regulation (Online Supplementary Table 1 ). Six of them are known to drive cell cycle progression and one gene causes G0/G1 cell cycle arrest. [19] [20] [21] [22] [23] The cell cycle promoting genes including cyclins, kinases, and small G-protein superfamily members were expressed at 1.3-to 1.7-fold higher levels in Peg-G-CSF-mobilized CD34
+ cells compared to their G-CSF-mobilized counterparts. On the other hand, the expression level of the hematopoietic cellspecific inhibitory cell cycle modulator membrane spanning four protein family group member A3 (MS4A3) 20 was + cells. We did, however, find a higher expression level of cyclin D3 in G-CSF-mobilized cells. This might be due to lineagedependent overexpression, as cyclin D3 is upregulated through erythroid-megakaryocytic differentiation.
22 In summary, the gene expression pattern suggests higher cell cycle activity in Peg-G-CSF-mobilized cells.
Peg-G-CSF-mobilized peripheral blood stem cells have a greater cycling activity
In order to examine whether the higher expression levels of proliferation-associated genes in Peg-G-CSF-mobilized cells are functionally relevant, we performed cell cycle analyses. In line with the gene expression data we saw a significantly greater proportion of actively cycling CD34 + cells (S-phase) in the samples from patients given Peg-G-CSF than in those given G-CSF. The percentage of Peg-G-CSF-mobilized CD34 + cells in G0/1 phase was significantly smaller (Figure 4) . Checking for functional differences also in hematopoietic stem cells ( Figure 5B 
Elevated expression levels of HOXA9 and GATA3 in Peg-G-CSF-mobilized hematopoietic stem cells
After having found that the distinct gene expression profiles of Peg-G-CSF-and G-CSF-mobilized CD34 + cells are also reflected by differences in subset composition and functional properties, we next addressed the question of whether differential gene expression in CD34 + cells might also be a result of Peg-G-CSF-versus G-CSF-induced transcriptional changes in early hematopoietic stem cells. We 
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BFU-E/CFU-GM ratio (log scale) ence was not statistically significant ( Figure 5A ). In contrast to the situation in the overall CD34 + cell population, the β-globin gene and KLF1 were not differentially expressed in the Lin -, CD34 + , CD38
-hematopoietic stem cell subset suggesting that they might be affected at later developmental stages. Taken together, these findings demonstrate that, compared to G-CSF stimulation, stimulation with Peg-G-CSF not only leads to mobilization of CD34 + cells with distinct subset compositions but also to different expression levels of transcriptional key regulators in Lin   -, CD34   +   , CD38 -hematopoietic stem cells.
Discussion
Here, we compared the effects of stimulation with Peg-G-CSF and unconjugated G-CSF on mobilized hematopoietic stem cells as well as their progeny. In Peg-G-CSFmobilized CD34 + cells, we found a gene expression pattern reflecting a developmentally earlier progenitor cell type, including the HOX family of homeobox genes, MEIS1 and MLL. These genes are expressed at high levels in hematopoietic stem and immature progenitor cells, thus suggesting a greater proportion of early, uncommitted stem and immature progenitor cells within the CD34 + cell population. [24] [25] [26] [27] [28] [29] Differences in the expression levels of these genes between Peg-G-CSF and G-CSF-mobilized cells were relatively small (see Online Supplementary Table 1) . Nevertheless, we and others have previously shown that even modest differences in the expression levels of transcription factors involved in hematopoiesis can lead to altered gene expression with a substantial influence on stem cell differentiation and function.
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In contrast, genes associated with erythroid and later stages of myeloid differentiation were expressed at lower levels. Of these genes, defensins ␣ 1, 3 and 4 play a pivotal role in neutrophil defense mechanisms 34, 35 and transcription factors C/EBP ␤ and ␦ are crucially involved in the maturation of cells commited to the myeloid lineage.
36-38 Accordingly, matrix metalloproteinases 8 (MMP8) and 9 (MMP9) were expressed at lower levels. MMP8 is a gene under C/EBP family control and expressed late in the myeloid maturation pathway. 38 Its family member MMP9 promotes differentiation at an earlier stage. MMP9 acts on hematopoietic stem cells via release of soluble kit ligand and induces transition from a quiescent to a proliferative stage, thereby favoring differentiation. 39 In line with the gene expression profile, analysis of the CD34 + subset composition of Peg-G-CSF-mobilized cells showed significantly greater proportions of hematopoietic stem cells and common myeloid progenitors, and a lower proportion of megakaryocyte erythrocyte progenitors. For functional corroboration of these findings we performed clonogenic assays and found a significantly lower BFU-E/CFU-GM ratio after plating of Peg-G-CSF-mobilized CD34 + cells compared to cells mobilized by unconjugated G-CSF. This finding is indicative of a higher proportion of myeloid progenitor cells and a smaller proportion of progenitor cells committed to the erythroid lineage within the Peg-G-CSF-mobilized CD34 + cells and demonstrates the functional relevance of the observed differential gene expression profiles and progenitor subset composition. Higher levels of expression of genes functionally important for hematopoietic stem cells were found not only in the CD34 + cells but also in highly purified hematopoietic stem cells after mobilization with Peg-G-CSF, suggesting enhanced long-term repopulating ability. 28, 40 This might explain the results of a recent clinical trial in which the authors found significantly greater leukocyte, reticulocyte and platelet counts on day 100 after initial engraftment following transplantation of Peg-G-CSF-mobilized autografts compared to grafts mobilized by unconjugated G-CSF. 41 Of interest, the number of Peg-G-CSF mobilized CD34 + cells transplanted was even smaller than the number of G-CSF-mobilized cells (p=0.0575). Hence, it was assumed that different biological functions of Peg-G-CSFmobilized cells may have accounted for these observations. 41 Looking at the engraftment kinetics of the patients whose mobilized stem and progenitor cells were analyzed here in our study, we also found significantly higher white blood cell count on day 100 post-transplantation in patients given Peg-G-CSF. At that time the median white cell count was 6.0×10 3 /µL after transplantation of Peg-G-CSF mobilized cells compared to 3.3×10 3 /µL after transplantation of G-CSF mobilized cells (p=0.03). Platelet counts and hemoglobin levels were also higher, although not statistically significantly so. However, due to the small sample size, these observations need to be substantiated in larger, randomized clinical trials. Of interest, mobilization of greater proportions of hematopoietic stem cells with superior long-term repopulating capacity have also been described for other mobilizing agents such as CXCR4 antagonists and GROβ, either used as single agents or in combination with G-CSF. [42] [43] [44] Apart from the superior long-term repopulating capacity, these cells also show accelerated short-term hematopoietic recovery. At first glance, this finding seems surprising as one would expect that more mature hematopoietic progenitor cells rather than immature primitive hematopoietic stem cells would contribute to accelerated short-term hematopoietic recovery. 45 However, other studies also found that not only long-term marrow recovery but also rapid shortterm recovery depends on hematopoietic stem cells.
46-48
In this context, it may be asked whether platelet recovery is impaired after transplantation of Peg-G-CSF-mobilized cells due to a significantly smaller proportion of megakaryocyte erythrocyte progenitors. Looking at the engraftment kinetics after transplantation of the grafts analyzed here, neither short-term nor long-term thrombocytopenia was observed. However, this finding also needs to be confirmed in larger randomized clinical trials. Peg-G-CSF-mobilized cells had a higher cell cycle activity compared to their G-CSF mobilized counterparts, consistent with the gene expression profile. Initially, this finding was puzzling since Peg-G-CSF-mobilized CD34 + cells contained a greater proportion of hematopoietic stem cells, which are generally considered quiescent and even these Peg- G-CSF-mobilized Lin   -, CD34   +   , CD38 -cells showed a greater proportion of cells in the S and G2/M phases of the cell cycle. However, Shojaei et al. have recently demonstrated a higher reconstitution ability of hematopoietic stem cells with increased cycling frequency, 49 which is in line with our data.
Searching for the underlying mechanism that may account for the different transcriptional and functional phenotypes of Peg-G-CSF-mobilized cells, it has been previously shown in a murine G-CSF receptor knock-out model that Peg-G-CSF and G-CSF exert their pharmacological effects via the same G-CSF receptor. 50 Thus, the different effects of G-CSF and Peg-G-CSF do not seem to be related to activation of different receptors. Neither absolute CD34
+ cell count/µL peripheral blood nor total CD34 + cell yield seems to be differentially affected by Peg-G-CSF and G-CSF as we found no significant differences after mobilization with Peg-G-CSF and G-CSF, in line with data reported previously for steady state-and cytotoxic mobilization. 51, 52 Of note, CD34 + subset composition after Peg-G-CSF and G-CSF mobilization described here was not addressed in those studies referenced above.
Interestingly, in a recent randomized clinical trial the effect of continuous intravenous administration vs. daily single subcutaneous doses of G-CSF on CD34 + cell mobilization was examined. 53 The authors found that CD34 + cell peak concentrations were reached 2 days earlier following continuous intravenous G-CSF administration compared to daily subcutaneous injections. These findings and the mobilization kinetics observed following the administration of Peg-G-CSF suggest that the timecourse of stimulation (pulsatile versus continuous), rather than a dose-related mechanism, might account for the distinct effects of Peg-G-CSF and G-CSF on stem and progenitor cells.
In conclusion, stimulation with Peg-G-CSF versus G-CSF, despite the same active compound, leads to altered gene expression of key regulatory genes and different functional properties of mobilized hematopoietic stem cells as well as their progeny. This, combined with a different subset composition of Peg-G-CSF-mobilized CD34 + stem and progenitor cells, may account for the distinct functional properties and differentiation patterns observed. These findings might explain the recently reported different clinical properties and engraftment kinetics of Peg-G-CSF-mobilized cells after autologous transplantation.
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